Ranibizumab (Lucentis) vs Aflibercept (Eyelea) for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in rural clinical practice
{"title":"Ranibizumab (Lucentis) vs Aflibercept (Eyelea) for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in rural clinical practice","authors":"N. Clements","doi":"10.37912/waggajom.0201.12","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":315668,"journal":{"name":"Wagga Wagga Journal of Medicine","volume":"57 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wagga Wagga Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37912/waggajom.0201.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
